Tech Center 1600 • Art Units: 1614 1628
This examiner grants 42% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18002572 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | Final Rejection | Novartis AG |
| 18040171 | METHODS OF TREATMENT USING FUROSEMIDE | Non-Final OA | scPharmaceuticals Inc. |
| 19243756 | PHARMACEUTICAL COMPOSITION OF ANTIPLATELET DRUG, AND USE THEREOF | Final Rejection | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17603145 | AGENT TARGETING DOUBLE-MEMBRANE ORGANELLE DNA | Final Rejection | JUNTENDO EDUCATIONAL FOUNDATION |
| 18006584 | USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND FOR PREVENTING, ALLEVIATION, OR TREATING MASTOCYTOSIS | Final Rejection | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17996343 | STABLE DIGLYCERIDE EMULSIONS AND METHODS FOR TREATING ORGAN INJURY | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 17528050 | Methods of Treating Prostate Cancer | Non-Final OA | Janssen Pharmaceutica NV |
| 17313938 | METHOD OF PERSONALIZED TREATMENT FOR CARDIOMYOPATHY AND HEART FAILURE AND OTHER RELATED DISEASES BY MEASURING RENIN ACTIVITY, PRO-RENIN, PRO-RENIN RECEPTOR LEVELS IN BLOOD | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17794823 | NOVEL COMPOUND AND USE THEREOF | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18009128 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PHOTODERMATOSIS | Final Rejection | MITSUBISHI TANABE PHARMA CORPORATION |
| 17440895 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | Non-Final OA | Cornell University |
| 18007308 | THERAPEUTIC USES OF GLUCOCORTICOIDS WITH ANABOLIC EFFECTS IN SKELETAL MUSCLE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18021643 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | Final Rejection | BIOGEN MA INC. |
| 18621976 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | Final Rejection | Tenax Therapeutics, Inc. |
| 17890130 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | Non-Final OA | Pharmacosmos Holding A/S |
| 16478552 | COMPOSITIONS AND METHODS FOR CONTROLLING NATURAL KILLER CELL ACTIVATION AND FUNCTION | Final Rejection | BAR ILAN UNIVERSITY |
| 18025433 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR | Final Rejection | UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS |
| 17915444 | Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin | Non-Final OA | Sorrento Therapeutics, Inc. |
| 18509935 | USE OF N-ACETYLCYSTEINE TO TREAT CNS DISORDERS | Non-Final OA | Burke Neurological Institute |
| 18487237 | COMBINATION FOR USE IN TREATING CANCERS | Non-Final OA | MAPKURE, LLC |
| 18285282 | QUINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | Non-Final OA | NANJING SHUPENG LIFE SCIENCE CO., LTD. |
| 17856311 | ENHANCER OF PHOTODYNAMIC EFFECT IN ALA-PDT OR ALA-PDD | Final Rejection | SBI PHARMACEUTICALS CO., LTD. |
| 18041328 | PHYTONADIONE COMPOSITIONS | Non-Final OA | CIPLA LIMITED |
| 17798131 | PHARMACEUTICAL COMPOSITION FOR INHIBITING INFLAMMATORY RESPONSE COMPRISING HYDROXYUREA | Final Rejection | BIONOXX INC. |
| 17746537 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | Final Rejection | Cereno Scientific AB |
| 18356972 | PARENTERAL TREATMENTS INVOLVING AMINOADAMANTANE DERIVATIVES | Non-Final OA | Shinkei Therapeutics, Inc. |
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | Final Rejection | ZEVRA DENMARK A/S |
| 18251336 | TOPICAL ADMINISTRATION OF 2-(DIETHYLAMINO)ETHYL 2-(4-ISOBUTYLPHENYL)PROPRIONATE FOR TREATMENT OF DISEASES | Non-Final OA | Chongxi Yu |
| 18034144 | APPLICATION OF BZP IN TREATMENT OF ISCHEMIC CARDIOVASCULAR AND CEREBRAL VASCULAR DISEASES | Non-Final OA | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy